Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Medivir develops innovative therapies targeting areas of high unmet medical need. Its most advanced asset is fostroxacitabine bralpamide (fostrox), a novel treatment for patients with advanced hepatocellular carcinoma (HCC) whose tumours have progressed despite first-line (1L) therapy. In addition, the company is developing a cathepsin K inhibitor, MIV-711, as a potential treatment for osteogenesis imperfecta and Perthes disease. Beyond its internal programmes, Medivir has partnered assets with companies including, Biossil, Infex Therapeutics, and Vetbiolix.
Key industry drivers
Upcoming patent expiries on several high-selling drugs are expected to drive strong industry demand for new pipeline assets
Demand for new and more effective therapies
Industry outlook
A global ageing population supports growing underlying demand for pharmaceutical treatments
The global medicines market is projected to grow at a CAGR of 5–8% through 2030 (IQVIA).
Key peers
We consider BioInvent, Cantargia, Egetis Therapeutics, Faron Pharmaceuticals and Vicore Pharma to be Medivir’s closest peers
Name
Capital
Votes
Hallberg Management AB.
16.0 %
16.0 %
Carl Bennet
15.3 %
15.4 %
Linc
12.0 %
12.1 %
Nordea Funds
5.3 %
5.4 %
Claesson & Andrezen
3.9 %
3.9 %
Avanza Pension
3.3 %
3.3 %
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB